TR201907729T4 - Bir anti-çekirdekleştirici ajan içeren farmasötik bileşim. - Google Patents

Bir anti-çekirdekleştirici ajan içeren farmasötik bileşim. Download PDF

Info

Publication number
TR201907729T4
TR201907729T4 TR2019/07729T TR201907729T TR201907729T4 TR 201907729 T4 TR201907729 T4 TR 201907729T4 TR 2019/07729 T TR2019/07729 T TR 2019/07729T TR 201907729 T TR201907729 T TR 201907729T TR 201907729 T4 TR201907729 T4 TR 201907729T4
Authority
TR
Turkey
Prior art keywords
nucleating agent
pharmaceutical composition
composition containing
salt
drug
Prior art date
Application number
TR2019/07729T
Other languages
English (en)
Inventor
M Artino Laura
T Cruanes Maria
Xu Wei
Zhu Honggang
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36565788&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR201907729(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of TR201907729T4 publication Critical patent/TR201907729T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Katı dozaj formlarında oral uygulamaya yönelik olarak uygun farmasötik bileşimler açıklanır. Bileşimler, bir tuz formunda bir etkili miktarda bir ilaç bileşiği içerir, burada ilaç tuzu belirli pH koşulları altında ilaç bileşiğinin bir daha az çözünebilir formuna dönüştürülmesi ve bir anti-çekirdekleştirici ajan ile karakterize edilir.
TR2019/07729T 2004-12-03 2005-12-02 Bir anti-çekirdekleştirici ajan içeren farmasötik bileşim. TR201907729T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US63285904P 2004-12-03 2004-12-03

Publications (1)

Publication Number Publication Date
TR201907729T4 true TR201907729T4 (tr) 2019-06-21

Family

ID=36565788

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/07729T TR201907729T4 (tr) 2004-12-03 2005-12-02 Bir anti-çekirdekleştirici ajan içeren farmasötik bileşim.

Country Status (9)

Country Link
US (1) US8771733B2 (tr)
EP (2) EP1819323B2 (tr)
JP (3) JP2008521929A (tr)
CN (1) CN101068533B (tr)
AU (1) AU2005311714B2 (tr)
CA (1) CA2588465C (tr)
ES (1) ES2727577T3 (tr)
TR (1) TR201907729T4 (tr)
WO (1) WO2006060681A2 (tr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070085702A (ko) * 2004-12-03 2007-08-27 머크 앤드 캄파니 인코포레이티드 Ｕｇｔ1ａ1에 의해 대사된 약물의 약력학을 개선시키기위한 아타자나비르의 용도
MX2007006635A (es) 2004-12-03 2007-06-19 Merck & Co Inc Formulacion farmaceutica de inhibidores dela carboxamida vih integrasa que contienen una composicion que controla la velocidad de liberacion.
US8771733B2 (en) 2004-12-03 2014-07-08 Merck Sharp & Dohme Corp. Pharmaceutical composition containing an anti-nucleating agent
UA87884C2 (uk) 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
CN101595133B (zh) * 2006-10-27 2012-11-14 比利时胶囊公司 羟丙基甲基纤维素硬胶囊及制备方法
CN101197832B (zh) * 2007-12-13 2012-01-25 华为技术有限公司 一种实现iptv业务的方法、***、装置
EP2438062B1 (en) 2009-06-02 2015-07-29 Hetero Research Foundation Process for the preparation of amorphous raltegravir potassium
IN2012DN03377A (tr) * 2009-10-26 2015-10-23 Merck Sharp & Dohme
SI2796458T1 (en) * 2010-04-01 2018-04-30 Teva Pharmaceutical Industries Ltd. CRYSTALINIC SODIUM RALTEGRAVIR SOLUTIONS
US9968607B2 (en) * 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
WO2021148992A1 (en) 2020-01-23 2021-07-29 Lupin Limited Pharmaceutical compositions of raltegravir
US20230277587A1 (en) * 2022-03-03 2023-09-07 Dermacisen, S.A. Food supplement for oral administration

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose
JPH0347124A (ja) * 1989-04-20 1991-02-28 Fujisawa Pharmaceut Co Ltd 経口吸収用製剤
CA2019324C (en) * 1989-07-10 1996-08-20 Robert L. Jerzewski Fosinopril tablet formulations
JP2707023B2 (ja) * 1992-07-01 1998-01-28 株式会社大塚製薬工場 経口吸収用製剤
WO2000018384A2 (en) † 1998-09-28 2000-04-06 Glaxo Group Limited Antiviral combinations comprising (s)-2-ethyl-7-fluoro-3-oxo-3,4-dihydro-2h-quinoxaline-1-carboxylic acid isopropyl ester and amprenavir
ATE411286T1 (de) * 1998-12-25 2008-10-15 Shionogi & Co Aromatische heterocyclen mit hiv integrase inhibierenden eigenschaften
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
AU783981C (en) * 2000-05-08 2007-05-03 Janssen Pharmaceutica N.V. HIV replication inhibitors
US7115565B2 (en) † 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
EP1441734B1 (en) 2001-10-26 2007-02-28 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Dihydroxypyrimidine carboxamide inhibitors of hiv integrase
US7169780B2 (en) 2001-10-26 2007-01-30 Istitute Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase
AU2003220186A1 (en) † 2002-04-10 2003-10-27 Merck And Co., Inc. Pharmaceutical compositions containing an hiv integrase inhibitor and a nonionic surfactant
BR0317749A (pt) 2002-12-27 2005-11-22 Angeletti P Ist Richerche Bio Composto, composição farmacêutica, e, uso de um composto
US20040224916A1 (en) † 2003-01-14 2004-11-11 Gilead Sciences, Inc. Compositions and methods for combination antiviral therapy
MX2007006635A (es) * 2004-12-03 2007-06-19 Merck & Co Inc Formulacion farmaceutica de inhibidores dela carboxamida vih integrasa que contienen una composicion que controla la velocidad de liberacion.
US8771733B2 (en) 2004-12-03 2014-07-08 Merck Sharp & Dohme Corp. Pharmaceutical composition containing an anti-nucleating agent
UA87884C2 (uk) 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
KR20070085702A (ko) 2004-12-03 2007-08-27 머크 앤드 캄파니 인코포레이티드 Ｕｇｔ1ａ1에 의해 대사된 약물의 약력학을 개선시키기위한 아타자나비르의 용도
US9968607B2 (en) 2011-04-25 2018-05-15 Hetero Research Foundation Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof

Also Published As

Publication number Publication date
AU2005311714A1 (en) 2006-06-08
EP1819323B2 (en) 2023-03-22
AU2005311714B2 (en) 2010-09-30
JP2008521929A (ja) 2008-06-26
CN101068533B (zh) 2011-04-27
ES2727577T3 (es) 2019-10-17
EP3165220A1 (en) 2017-05-10
EP1819323A2 (en) 2007-08-22
CA2588465A1 (en) 2006-06-08
JP2012184250A (ja) 2012-09-27
US8771733B2 (en) 2014-07-08
EP1819323A4 (en) 2012-07-18
US20080118559A1 (en) 2008-05-22
WO2006060681A2 (en) 2006-06-08
JP2013063999A (ja) 2013-04-11
EP1819323B1 (en) 2016-11-16
WO2006060681A3 (en) 2006-10-12
EP3165220B1 (en) 2019-04-03
CA2588465C (en) 2013-10-01
CN101068533A (zh) 2007-11-07

Similar Documents

Publication Publication Date Title
TR201907729T4 (tr) Bir anti-çekirdekleştirici ajan içeren farmasötik bileşim.
BRPI0508579A (pt) composto, composição farmacêutica, e, uso de um composto
CO6300932A2 (es) Composicion solida termoestable que comprende sustancias mejoradas de permeabilidad para ingredientes farmaceuticos activos de permeabilidad deficiente
NZ597237A (en) Sublingual apomorphine
DE602005025755D1 (de) Irbesartan enthaltende pharmazeutische zusammensetzung
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
DK2041133T3 (da) Derivater af imadazol [1,2-A] pyridine-2-carboxamider, fremstilling deraf og anvendelse deraf i terapeutik
ATE410424T1 (de) Spirocyclische cyclohexan-derivate
RS54543B1 (en) Fast acting gastric acid secretion inhibitor
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
RS52457B (en) POWDER FORMULATION FOR VALGANCICLOVIR
MX2007006635A (es) Formulacion farmaceutica de inhibidores dela carboxamida vih integrasa que contienen una composicion que controla la velocidad de liberacion.
UA122762C2 (uk) Пероральна композиція 9-[(2,2-диметилпропіламіно)-метил]-міноцикліну або його солі, тверда пресована дозована форма, композиція для ін'єкцій, застосування та спосіб приготування фармацевтичної композиції
MY140630A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
MY142792A (en) Azolopyridin-2-one derivatives as inhibitors of lipases and phospholipases
DE60319707D1 (de) Pharmazeutische zusammensetzung enthaltend ein benzimidazol-derivat gemischt mit mikrokristalliner cellulose
HK1167388A1 (en) Anticancer compound and pharmaceutical composition containing the same
IL191670A0 (en) Compounds for the inhibition of apoptosis
EA200600377A1 (ru) Новая композиция
TR200803177A2 (tr) Antihiperglisemik etkili metformîn - pioglitazon formülasyonu.
WO2007145563A8 (en) Benzimidazole derivatives which are to be used as antagonist for the cb1-receptor
TW200738703A (en) 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
HRP20090102T3 (en) Improved pharmaceutical composition containing ace inhibitor and method for the preparation thereof
EA200970020A1 (ru) Пероральная фармацевтическая композиция из активного вещества плохо растворимого в воде